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ABSTRACT 
Background: Only few mutations associated with qualitative protein S deficiency 
have been already described. Sensitivity and specificity for type II PROS1 mutations 
of commercially available reagents for measuring PS activity are not well established 
. Whether these mutations are significant risk factors for thrombosis remains an  
unresolved question. Methods: In order to address the first point, we present and 
discuss the results of PROS1 analysis performed in the 30 probands with type II PS 
inherited deficiency suspicion and 35 relatives, studied in our laboratory between 
2000 and 2008.  In order to investigate the influence of type II mutations on the 
coagulability level, thrombin generation tests  were performed on plasma from 102 
PROS1 type II, type I/III, or PS Herleen mutation heterozygous carriers and controls. 
Results: Mutations (12 novel, 6 already described) which likely explain the qualitative 
phenotype, were found in 27 (90%) among the 30 probands studied. In relatives, 
78% of heterozygotes presented with a type II phenotype. An APC resistance 
phenotype was documented in type II and type I/III defects heterozygous carriers; 
however, the effect of type II was milder than the effect of type I/III PS mutations. 
Conclusions: PS functional assay (Staclot PS, Stago) was efficient in screening for 
PROS1 type II defects, particularly in probands. A  significant positive  influence of 
type II mutations on ex vivo thrombin generation was demonstrated. However, 
whether these mutations increase the risk of venous thromboembolism requires 
further investigation. 
  
INTRODUCTION 
            Protein S (PS) is a cofactor of activated protein C (APC) in the proteolytic 
inactivation of blood coagulation factors Va (FVa) and VIIIa (FVIIIa), thus providing a 
negative feedback on thrombin generation and making the APC/PS pathway 
essential for normal haemostasis. The anticoagulant activity of PS might also be 
direct, i.e independent of APC, as PS is also a nonenzymatic cofactor for tissue 
factor pathway inhibitor (TFPI) in the inhibition of factor Xa (FXa), and in addition, 
directly limits thrombin generation by binding to and inhibiting FXa and FVa in the 
prothrombinase complex [1].   
              PS deficiency (MIM:#176880) is a recognized genetic risk factor for venous 
thromboembolism (VTE) [2]. It is an autosomal dominant trait with incomplete 
penetrance and variable clinical and biochemical expression, which affects 2% to 
10% of patients with thrombosis in Caucasian populations [3]. It could be more 
frequent in Asian populations [4]. According to plasma levels of total PS (TPS), free 
PS (FPS) antigen and PS activity (PSA), three types of PS deficiency are defined: 
type I and III are quantitative deficiencies; type II or qualitative PS deficiency is 
characterized by normal FPS level and reduced PSA, and therefore a decreased 
PSA/FPS ratio due to the presence of a dysfunctional variant in plasma. Type II 
deficiency seems rather uncommon ; to the best of our knowledge only sixteen 
mutations able to explain impaired PS APC cofactor activity have been found in 
patients with a type II phenotype, and no case of PS-deficient subject with impaired 
direct anticoagulant activity has been reported so far; most type II mutations are 
unsurprisingly located at positions known to be important for the protein function, i.e:  
in the propeptide cleavage site (p.Arg40Leu, p.Arg41His) [5] [amino acid numbering 
using the HUGO recommendations], in the GLA domain (p.Lys50Glu, p.Gly52Asp, 
  
p.Thr78Met) [5, 6], in the thrombin sensitive loop (TSR) (p.Arg101Cys) [7] and in the 
epidermal-growth factor (EGF) like domains, [p.Thr144Asn in EGF1, in EGF2 
p.Asp157Gly, p.Cys175Phe, and p.Lys196Glu in EGF2, p.Cys217Tyr, p.Tyr225Cys in EGF3, p. 
Ile244-Asp245 del in EGF4] [5, 8, 9, 10]. A substitution in the donor splice site of intron 5 
(c.469+5G>A) leading to exon 5 skipping induces full loss of EGF1 [5].  In addition, two 
natural missense mutations at position 95, p.Gly95Glu  and p.Gly95Arg were reported in 
patients with mild decrease in the PSA/FPS ratio [5]. Type II PS inherited deficiency 
could be in fact more frequent than generally considered since PS functional assay is 
performed by a minority of laboratories in the screening for PS deficiency; the reason 
for measuring FPS level rather than PSA is “historical” due to insufficient specificity of 
the first generation of commercial PS activity assays. Moreover, no commercial 
reagent allowing direct PS activity measurement are available. However, it would be 
important to include searching for type II variants in thrombophilia screening if these 
variants do increase risk of thrombosis. 
                  The two objectives of the present study were: 1) to assess the usefulness 
of Staclot PS (Stago, Asnières, France) for screening for type II inherited deficiency; 
this assay is based on modified activated partial thromboplastin time (APTT). Diluted 
patient plasma is added to PS-depleted plasma in the presence of purified APC and 
factor Va, therefore the assay measures the APC dependent activity of PS; and 2) to 
gain insight on phenotypical consequences of PROS1 type II mutations. We report 
the results of PROS1 analyses performed in the  whole group of probands  with a 
suspicion of inherited qualitative PS abnormality studied in our laboratory between 
2000 and 2008 and in relatives. We also report the results of thrombin generation 
tests (TGTs) performed by calibrated automated thrombinography (CAT) [11] on 
plasma from 76 carriers of distinct PROS1 mutations,  including 26 with type II 
  
defects, and we compare thrombosis history in relatives with type II or type I/III 
defects. 
 
 
SUBJECTS AND METHODS 
Subjects 
Subjects studied were initially referred to specialized French clinical 
haematology laboratories for thrombophilia screening in the context of unexplained 
personal or family history of thrombosis. Recording of clinical characteristics of the 
subjects including objectively confirmed episodes of venous thrombosis (VT) or 
pulmonary embolism (PE), and screening for biological risk factors for VT 
(antiphospholipid antibodies, antithrombin, protein C, protein S deficiency, the FV 
Leiden and the F2 G20210A mutations) were performed in each centre. Family 
history of VTE was defined by the occurrence of VT in at least one first degree 
relative. When an inherited PS deficiency was suspected, DNA and plasma samples, 
when available, were sent to our laboratory for PROS1 genotyping. An informed 
consent authorizing genetic analyses was obtained from every patient, according to 
the Helsinki declaration. 
Genetic study: In the period 2000-2008, we analyzed PROS1 in 30 probands 
(14 men, 16 women), mean age 44.7 (extreme values 16-73), in whom a PS inherited 
qualitative deficiency was suspected and 35 relatives from 15 of these kindreds. 
Plasma PS activity (PSA) and TPS levels  were measured using Staclot PS and 
Asserachrom TPS reagents (Stago). FPS level was measured using the FPS reagent 
from Instrumentation Laboratory (Milano, Italy) in two patients and using the 
Asserachrom FPS kit (Stago) in the others. PS type II inherited deficiency was 
suspected in probands based on the observation of a persistent decreased or 
  
borderline PSA and abnormal PSA/FPS ratio (< or =0.80) in the absence of factors 
susceptible to induce falsely low Staclot PS level (FVIII>250% [12], FV Leiden [13], 
antiphosholipid antibodies..). 
TGTs: TGTs were performed on plasma from: 26 subjects heterozygous for 
type II PROS1 mutations and 34 subjects with type I/III mutations previously 
identified by sequencing, one individual with a Multiplex Ligation-dependent Probe 
Amplification (MLPA) profile suggesting heterozygosity for a complete deletion of the 
gene, 15 PS Herleen (Ser501Pro) heterozygous carriers, 7 relatives from these 
families who did not carry the mutation present in their pedigree. They did not receive 
hormonal treatment and had no other biological risk for thrombosis. The subjects 
were selected on their genotype and on availability of plasma samples for TGTs. A 
last group consisted of 19 “healthy subjects” with no personal history of thrombosis 
and no biological risk  factor for VT, studied in our laboratory during the same period, 
Symptomatic subjects were studied at distance from thrombosis events, at least 1 
month after stopping oral anticoagulant treatment.  
All samples for PS assessment and thrombin generation work were taken in the 
absence of anticoagulant treatment. 
        PROS1 defects carrying and thrombosis history: We compared thrombosis 
history in adult (> 15years old) relatives from all families with PROS1 mutations 
associated with type II (36 relatives from 9 families) or quantitative PS deficiency  (47 
relatives from 11 families) and no other risk factor for thrombosis studied in our 
laboratory between 2000 and 2010, for whom full clinical information was available. 
Mutations responsible for quantitative deficiency were premature stop-codons or 
missense detrimental mutations already described.  
 
 
  
 
PROS1 analysis 
           In the probands, the exons, the intron-exon boundaries and 700bp of the 
proximal promoter of the functional gene for PS, PROS1 (GeneID: 5627, 
MIM#176880) were studied by direct sequencing as previously described [14, 15]. In 
family members, gene analysis was restricted to the region found abnormal in the 
proband. Mutations are numbered according to the HUGO recommendations for 
mutation nomenclature (http://www.hgvs.org) based on the start codon (ATG) of the 
first translated methionine. Amino-acid numbering according to the ISTH database 
[5], based on the mature protein, is obtained by substracting 41 for residues of the 
mature protein or 42 for residues that belong to signal peptide and propeptide. 
 
Thrombin generation tests 
              Venous blood was collected on 0.109M sodium citrate in the recruiting 
centres. Platelet poor plasma was prepared by double-centrifugation for 15mn at 
2000-2500g, at temperature between 15 and 22°C, within 2hours from blood 
sampling,  then stored frozen in small aliquots at temperature <-30°C. For every 
patient, all clotting tests were performed on a unique plasma sample, within 2 hours 
after thawing. Thrombin generation in the presence or absence of  activated protein 
C (APC) was measured according to the method described by Hemker et al. [11] 
using the reagents PPP (-a mixture of phospholipids (PL) and tissue factor (TF)-), 
thrombin calibrator and the fluorogenic substrate FluCa from Thrombinoscope 
(Maastricht, Netherlands), following the manufacturer’s instructions except for the 
following modification: thrombin generation was triggered by the addition of 20ul PPP 
reagent to 80ul plasma in the presence of 5ul APC (10ug/ml) (Hyphen Biomed, 
  
Neuville s/Oise, France) or 5ul 0.15MNaCl. Fluorescence measurements were 
performed after addition of 20ul of FluCa. Final concentrations of PL and TF in the 
mixture were 4.8pM TF and 3.9uM PL. The parameters studied were the area under 
the curve (endogenous thrombin potential: ETP), the lag time, time to peak (PT), 
peak height  and the start tail (ST), time at which thrombin generation has come to an 
end. Inter-assay coefficients of variation (CV) calculated on the results obtained for a 
normal plasma pool in 2 series of respectively 7 and 6 independent runs were <10% 
for ETP-APC, peak height-APC, ST-APC, PT +/-APC, and 10-20% for the other 
parameters studied. CV of the ETP -APC/+APC ratio was 15%. 
                 PSA, factor II (FII), FV, FVIII, F-TFPI, TPS, FPS, and fibrinogen level when 
not previously determined on fresh plasma, were also measured on this plasma 
sample, using reagents from Stago (Asnières, France). FV level was checked in 
order to verify that storage did not alter the quality of plasma samples 
 
Statistical analysis of TGT results  
                 Distribution of each parameter was tested for normality and transformed 
variables were used for non-parametric distributions. Mean levels were given in 
arithmetic form. Analysis of variance and Fisher test were used to compare the 
baseline characteristics of subjects. Multiple comparison procedures including the 
Bonferroni correction were used to assess the differences in thrombin generation 
parameters between subgroups. Stepwise multiple linear regressions were used to 
assess the relative contribution of haemostatic variables to the difference in each 
thrombin generation parameter between subgroups. Statistical analysis used 
procedures available in the Statistical Analysis System (SAS) software (SAS Institute, 
Inc., Cary, NC, USA.  Annual incidences of VTE were calculated by dividing the 
  
number of symptomatic relatives by the total number of observation years. 
Observation time was defined as the period from the age of 15 years until the end of 
the observation period, or until the first episode of VTE. Freedom of VTE was 
analysed by the Kaplan-Meier method. 
 
RESULTS 
Genetic study 
         Information concerning thrombosis history, and plasma PS levels in the 
probands and mutated family members are shown in Table 1. A personal history of 
VT was present in 28 probands; P10, asymptomatic, was explored because of a 
family history of VT; P24 had a history of distal arterial thrombosis in association with 
a systemic lupus. Other biological risk factors for thrombosis were present in 3 
probands (heterozygosity for a detrimental PROC  mutation in P22 and for the F2 nt 
20210G>A substitution inP24 and 29), but in no relative. Thrombosis antecedents 
were present in one 1st degree relative in 9 families, and in 4 relatives in another 
kindred.  
         Nineteen different mutations were found in 29 probands and in 28 relatives. 
Fifty-three subjects were heterozygotes. Two individuals were homozygotes, and two 
others were compound heterozygotes. We found 12 mutations [c.143A>G (p.Glu48Gly),  
c.271T>C (p.Ser91Pro), c.359A>G (p.Gln120Arg), c.360G>C (p.Gln120His), c.358C>G 
(p.Gln120Glu), c.469G>C (p.Asp157His), c.469G>A (p.Asp157Asn), c.481T>C (p.Cys161Arg), 
c.538G>A (p.Gly180Arg), c.566G>A (p.Gly189Asp), c.611A>C (p.Glu204Ala), c.656A>G 
(p.Asn219Ser) ] which, to the best of our knowledge, were not previously reported. We 
also found 6 previously described detrimental changes [c.119G>T (p.Arg40Leu), c.233C>T 
(p.Thr78Met), c.284G>A (p.Gly95Glu),  c.301C>T (p.Arg101Cys), c.635G>A (p.Cys217Tyr) , 
  
c.728A>T which induces the loss of Ile244 and Asp245] and a substitution previously reported 
as a neutral polymorphism [c.698G>A (p.Arg233Lys)].  
         No mutation was found in 7 asymptomatic relatives which presented with 
normal PS levels.  
 
Thrombin generation tests 
Relatives non-carrier of PROS1 mutations and healthy subjects  were combined 
in the analyses since no significant differences in descriptive characteristics or TG 
parameters were found among the subjects. 
General characteristics are reported in Table 2. Age, factor II, FV, FVIII, 
fibrinogen mean levels were similar among the groups. F-TFPI level  was higher in 
type II than in type I/III deficient patients. As expected, PSA and FPS levels were 
clearly low in PROS1 type I/III mutation carriers and mildly decreased in PS Herleen 
carriers. In type II mutation carriers, mean PSA was borderline. PSA/FPS ratio was 
significantly decreased in patients with type II mutations.  Sixty-six among these 102 
subjects were asymptomatic.  
Multiple regression analysis revealed significant positive influence of FII (r=0.44, 
<0.001, and r=0.29, p=0.003) and fibrinogen (r=0.39, p=0.002 and r=0.25, p=0.01) on 
ETP and peak height in the absence of APC; PS  (PSA r=-0.23, p=0.02, FPS r=-0.18, 
p=0.06) and FV (r=0.29, p=0.02) had a mild significant influence on ETP only and 
FVIII on peak height only (r=0.21, p=0.03). In the presence of APC, ETP and peak 
height were highly dependent on PS (PSSTA: r= -0.69 p<0.0001, FPS: r=-0.64, 
p<0.0001) and F-TFPI (r=-0.43, p<0.0001), and  a mild influence of FVIII  on both 
parameters was observed (r=0.21, p=0.03). 
  
Overall comparison demonstrated significant inter-group differences for ETP 
and no significant difference in lag time or start tail. Table 3 shows the influence of 
PROS1 defects on ETP and peak height. Both the statistical significance and the 
means were adjusted for age, sex, personal history of VTE,  and for FII, fibrinogen, 
FV and FVIII, which had significant influence on these parameters. ETP in the 
absence of APC was 20% higher in carriers of PROS1 mutations than in non-
mutated subjects, whatever the type of defect. Highly significant differences between 
type I/III or type II mutation carriers and non-mutated subjects for both ETP and peak 
height in the presence of APC and for ETP and peak ratios (demonstrating an APC 
resistance) were observed (p<0.0001). Thrombin generation in the presence of APC 
was indeed 3 fold higher in patients with PS type I/III deficiency than in PS Herleen 
carriers or subjects without mutations and 2 fold higher in patients with type II 
mutations. Significance was lost after adjustment on PSA which explained more than 
80% of inter-group differences in the presence of APC, demonstrating that in this 
condition the effects on TGT are mainly due to PS defects, and  30-60% of inter-
group differences, showing a lower contribution,  in the absence of APC. Further 
adjustment on F-TFPI did not change the results. No significant differences between 
PS Herleen carriers and non mutated subjects were observed. There was no 
significant difference in TGT parameters between individuals who had suffered VT 
and those who had not. 
 
PROS1 mutations and thromboembolic history 
             Characteristics of the relatives studied and incidences of VT events (deep or 
superficial VT or PE) are given in Table 4, and event free survival curves for VT are 
shown in Figure 1. The 15 non-mutated relatives from the 30 families studied were 
  
asymptomatic. Eight among 37 relatives with type I/III mutation and 2 among 21 
relatives with type II mutation displayed a thrombosis history.  Annual incidence of VT 
in relatives with type I/III mutation  was 0.56 (0.17-0.95). Heterozygosity for a PROS1 
type I/III mutation conferred an odds ratio for VT of at least 4.3  (95% CI 0.3-69.0) as 
compared with the non-mutated relatives from the type I/III group. However, these 
estimations are not  fully reliable due to the absence of VT event among non-carriers. 
Incidence was 2 fold lower in relatives with type II mutation [0.24 (0-0.58)]. However, 
the difference was non significant (p=0.22).  
 
DISCUSSION 
                The 12 novel mutations, which affect residues 48, 91, 120, 157, 161, 180, 
189, 204, or 219 could explain a qualitative deficiency for the following reasons:  
                 Firstly, the affected residues, except Ser 91, are highly conserved in PS 
among mammalian species.  
                 Secondly, most novel mutations (-except those at positions 204  and 219-) 
are located in regions of PS (GLA, TSR, EGF1 and 2)  known to be crucial for  APC 
cofactor activity [16-19].  Among these mutations, Glu 48, Ser 91 and Gln 120 are 
located “at strategic positions”. Glu 48 is located in a crucial ω loop of the GLA region 
involved in interaction of PS with anionic PL surfaces [16], and Ser 91 is located at a 
site where cleavage by thrombin leads to PS inactivation [17]. Gln 120 together with 
Asp 119 and Asp 136  in EGF1 could be part of the principal functional interaction 
site for APC [20]. A p. Gln 120 Ala variant expressed in vitro and analysed in a TG 
assay was recently reported to have severely reduced APC cofactor activity [20]. 
Residues 204 and 219 are located in EGF3 which has less understood functions. 
However, these residues belong to typical Ca2+ binding consensus sequences 
  
possibly important for the structural integrity of PS as specific cooperative effect of 
EGF2 and EGF3 for calcium binding have been demonstrated [21]. Moreover, a 
p.Glu204Gly PS variant expressed in vitro was previously reported to have 
decreased anticoagulant function [10]. In addition, functional importance of the EGF 
domains is supported by previous description of natural mutations associated with 
type II PS deficiency at positions 144, 157, 175, 196 and 217 [5].  
             Thirdly, p.Cys161Arg, p.Ser91Pro and p.Gly180Arg may induce significant 
modifications of the protein structure due to disruption of a disulfide bridge for the first 
one  or differences in physicochemical characteristics for the others.  
            Lastly, cosegregation observed in families with mutations at position 91, 189 
and 219 and observation of type II deficiency in unrelated carriers of distinct 
mutations at position 120 support their detrimental character.  
             Interestingly, among carriers of p.Gln120Glu, two consanguineous patients 
were homozygotes and another subject was a compound heterozygote, carrier of 
both p.Gln120Glu and p.Thr78Met mutations. Low PS antigen level in these patients 
suggests a significant effect of p.Gln120Glu on both function and expression or 
metabolism of PS. The consequences of p.Cys161Arg in the family reported here are 
not clear, with borderline FPS levels and normal PSA/FPS ratios observed in 3 
among 4 heterozygous carriers. However, a patient previously studied in our 
laboratory heterozygous for another mutation at the same position (p.Cys161Gly) (- 
not initially reported as type II-) displayed in fact also a qualitative phenotype 
(PSA/FPS: 0.5-0.75 on 2 different occasions) [5].  
                Five mutations (p.Arg40Leu, p.Gly95Glu p.Thr78Met, p.Arg101Cys, 
p.Ile244-Asp245 del) had been previously described, and found associated with type 
II deficiency [5, 7, 22].  
  
               p.Arg233Lys was the unique mutation found in probands 22 and 23. 
However, as Arg233Lys was previously reported to be a neutral polymorphism [5], its 
presence probably does not explain plasma levels. 
                Absence of mutation was observed in only one proband (P24) in whom an 
acquired PS abnormality cannot be excluded accounting for the clinical context 
(systemic lupus), even if  no antiphospholipid or anti PS IgG (Zymuphen anti PS IgG, 
Hyphen BioMed, Neuville s/Oise, France) could be detected.  
                 Finally, mutations possibly explaining decreased PSA/FPS ratios were 
found in 27 among the 30 probands (90%) studied documenting the usefulness of 
Staclot PS for type II mutation screening, when applied to probands with no cause of 
‘false positive” results (i.e FV Leiden, FVIII>250%) [12, 13]. In relatives, the assay 
was not 100% sensitive as illustrated by the observation of fully normal PSA  in 6 
among the 27 heterozygotes studied (carriers of Arg40Leu (3), Glu48Gly (1), 
Arg101Cys (1) or Asn219Ser (1) respectively). However, PSA/FPS ratio was 
decreased in 3 among them.  Possible explanations for “false-negative” results are 
the following: firstly, the nature of the assay, based on a modified APTT, therefore 
possibly sensitive to negative as well as positive interferences; secondly, a global 
increase in PS level due to acquired conditions; thirdly, a genetic origin: phenotypic 
variability in Thr78Met carriers was previously observed, and explained by the “mild” 
influence of the mutation on both secretion and function of PS [6]. A mild influence of 
the mutation could similarly explain phenotypic variability associated with 
heterozygosity for Arg40Leu or Lys50Glu  [5], or other mutations  reported here. 
                 We used thrombinography to gain insight into the influence of type II 
mutations carrying on procoagulant potential. It was previously reported that CAT 
monitoring performed at low TF concentration (1pM) in the absence of APC and at 
  
high concentration (10-15pM) in the presence of APC are conditions with an optimal 
sensitivity to the activity of the TFPI/PS system  [23, 24]. In such conditions, pooled 
plasma from heterozygous type I PS deficient individuals generated 3-5 fold more 
thrombin than normal plasma [25]. In accordance with this finding, in a large group of 
heterozygous carriers of type I/III mutations, we found a significant APC resistance in 
TGTs performed at 4.8pM TF, which can be fully explained by  PS defects. 
                 Interestingly, in the study by Castoldi et al., full length TFPI and PS low 
levels were simultaneously observed in PS type I deficient patients, and TFPI was 
shown to contribute significantly to the increased TG observed in PS deficient 
plasma. Full normalization of TG was only obtained through simultaneous 
normalization of both PS and TFPI levels [25]. More recently, Castoldi et al. reported 
that TFPI levels are reduced in type I but normal in type III PS deficiency [26]. In the 
present study, mean F-TFPI level was indeed lower in the 12 PS type I deficient 
subjects [mean (SD): 7.4 (3.5) ng/ml] than in the 23 type III deficient subjects [8.4 
(3.8)]; however, the difference was non significant and F-TFPI contribution to inter-
group ETP and peak height  variations was mild.  
                 At 4.8pM TF in the absence of APC, sensitivity of the assay to the activity 
of the TFPI/PS system  is milder. Seré et al, reported that, at 3.5pM TF, ETP 
increase was only 20%after full neutralization of PS [23]. This may explain why we 
observed relatively mild effects at 4.8pM and a weak contribution of PS defects  to 
inter-group ETP differences. 
                   PS Herleen contains a S501P mutation that results in loss of N-linked 
glycosylation at position 499. PS Herleen has a reduced half-life in vivo [27] which 
may explain the association of PS Herleen heterozygosity with mildly reduced levels 
of plasma FPS and the observation of clearly low FPS level in homozygotes [28]. 
  
Whether the risk of VT is increased in PS Herleen heterozygous subjects remains 
doubtful; the prevalence of the S501P mutation is indeed rather high in healthy 
populations (around 0.5%) and no significant association was found between PS 
Herleen carrying and VT [29]. PS Herleen allele may be in fact significantly involved 
in the occurrence of VT only in individuals who carry other genetic traits [28, 30]. We 
did not observe any influence of PS Herleen on TGT parameters except on ETP-
APC, supporting no more than a mild influence on procoagulant potential. 
                To the best of our knowledge, the influence of type II mutations on CAT 
parameters has not been studied yet. Our finding of a significant 2-fold increased 
ETP+APC and ETP ratio  in carriers of type II mutations compared to subjects with 
no defect or PS Herleen carriers is consistent with a procoagulant phenotype and 
suggests that type II inherited deficiency may be a risk factor for VT.  
               Recent studies on risk of a first VT event in carriers of PS type I/III inherited 
deficiency  reported annual incidences ranging from 0.27 to 1.5% in line with our own 
result [31-35]. To the best of our knowledge, the risk of VT associated with type II 
defects has not yet been studied. In the present study, no significant influence on the 
risk of VT could be demonstrated. However, the number of relatives investigated was 
small and should be increased for obtaining more reliable estimate of the risk. 
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